Literature DB >> 21345913

Human chorionic gonadotrophin regulates FGF2 and other cytokines produced by human endometrial epithelial cells, providing a mechanism for enhancing endometrial receptivity.

P Paiva1, N J Hannan, C Hincks, K L Meehan, E Pruysers, E Dimitriadis, L A Salamonsen.   

Abstract

BACKGROUND: Preimplantation cross-talk between a functional blastocyst and the endometrium is critical for successful blastocyst implantation. This interaction is mediated in part by endometrial cytokines/growth factors secreted by glandular epithelium into the uterine cavity. Recent evidence suggests that blastocyst-derived hCG may influence the endometrial milieu in conception cycles thereby enhancing receptivity and implantation success. This study investigated the effect of hCG on the secretory profile of a select cohort of 44 cytokines/growth factors from primary human endometrial epithelial cells (hEECs). These factors included those with both known and unknown roles during receptivity and implantation. The expression of one previously unknown hCG-regulated factor, fibroblast growth factor 2 (FGF2), in human endometrium and its effects on hEEC function were further examined.
METHODS: hEECs isolated from endometrial biopsies collected from fertile cycling women (n = 15) were treated ± recombinant hCG (0.2-20 IU/ml) for 48 h and conditioned media was quantitatively analysed using Luminex™ multiplex technology. FGF2 was further investigated by immunohistochemistry, western blot and cell-adhesion assays.
RESULTS: Of 44 cytokines/growth factors examined, 39 were produced by hEECs with a distinct profile. hCG (2 IU/ml) significantly increased the production of six factors, including those with known roles in receptivity and trophoblast function (interleukin-11), blastocyst migration and adhesion (CXCL10), blastocyst development (granulocyte macrophage colony-stimulating factor) and one unknown with respect to receptivity and implantation (FGF2). Up-regulation of known hCG-regulated proteins, vascular endothelial growth factor and leukaemia inhibitory factor, validated this study. Immunoreactive epithelial FGF2 increased across the menstrual cycle, being highest in secretory and first trimester pregnancy endometrium in vivo. FGF2 (100 ng/ml) stimulated phosphorylation of ERK1/2 in hEEC with no effect on ERK1/2 abundance and stimulated hEEC adhesion to fibronectin and collagen IV (components of blastocyst/trophectoderm extracellular matrix).
CONCLUSIONS: These findings clearly support roles for hCG and FGF2 in the blastocyst-endometrial cross-talk important for endometrial receptivity and blastocyst implantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21345913     DOI: 10.1093/humrep/der027

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  27 in total

Review 1.  G-CSF and stem cell therapy for the treatment of refractory thin lining in assisted reproductive technology.

Authors:  Youssef Mouhayar; Fady I Sharara
Journal:  J Assist Reprod Genet       Date:  2017-04-12       Impact factor: 3.412

Review 2.  Guidelines for the design, analysis and interpretation of 'omics' data: focus on human endometrium.

Authors:  Signe Altmäe; Francisco J Esteban; Anneli Stavreus-Evers; Carlos Simón; Linda Giudice; Bruce A Lessey; Jose A Horcajadas; Nick S Macklon; Thomas D'Hooghe; Cristina Campoy; Bart C Fauser; Lois A Salamonsen; Andres Salumets
Journal:  Hum Reprod Update       Date:  2013-09-29       Impact factor: 15.610

3.  Establishment and differentiation of long-term trophoblast organoid cultures from the human placenta.

Authors:  Megan A Sheridan; Ridma C Fernando; Lucy Gardner; Michael S Hollinshead; Graham J Burton; Ashley Moffett; Margherita Y Turco
Journal:  Nat Protoc       Date:  2020-09-09       Impact factor: 13.491

4.  Trophoblasts promote induction of a regulatory phenotype in B cells that can protect against detrimental T cell-mediated inflammation.

Authors:  Ruth Marian Guzman-Genuino; Tanya Dimova; Yuan You; Paulomi Aldo; John D Hayball; Gil Mor; Kerrilyn R Diener
Journal:  Am J Reprod Immunol       Date:  2019-10-06       Impact factor: 3.886

Review 5.  Extragonadal actions of chorionic gonadotropin.

Authors:  Prajna Banerjee; Asgerally T Fazleabas
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

6.  Role of the pregnancy-specific glycoprotein in regulation of the cytokine and chemokine profiles of intact mononuclear cells.

Authors:  M B Rayev; L S Litvinova; K A Yurova; N A Dunets; O G Khaziakhmatova; V P Timganova; M S Bochkova; P V Khramtsov; S A Zamorina
Journal:  Dokl Biol Sci       Date:  2017-09-01

Review 7.  Fertile ground: human endometrial programming and lessons in health and disease.

Authors:  Jemma Evans; Lois A Salamonsen; Amy Winship; Ellen Menkhorst; Guiying Nie; Caroline E Gargett; Eva Dimitriadis
Journal:  Nat Rev Endocrinol       Date:  2016-07-22       Impact factor: 43.330

8.  Human Endometrial Transcriptome and Progesterone Receptor Cistrome Reveal Important Pathways and Epithelial Regulators.

Authors:  Ru-Pin Alicia Chi; Tianyuan Wang; Nyssa Adams; San-Pin Wu; Steven L Young; Thomas E Spencer; Francesco DeMayo
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

9.  Investigating the Optimal Time for Intrauterine Human Chorionic Gonadotropin Infusion in Order to Improve IVF Outcome: A Systematic Review and Meta-Analysis.

Authors:  Mara Simopoulou; Konstantinos Sfakianoudis; Evangelos Maziotis; Petroula Tsioulou; Polina Giannelou; Sokratis Grigoriadis; Agni Pantou; George Anifandis; Panagiotis Christopoulos; Konstantinos Pantos; Michael Koutsilieris
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

10.  Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation.

Authors:  York Hunt Ng; Sophie Rome; Audrey Jalabert; Alexis Forterre; Harmeet Singh; Cassandra L Hincks; Lois A Salamonsen
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.